Why the study?
Cardiorenal syndrome causes damage to both organs with high morbidity and mortality, prompting investigation into biomarkers for early diagnosis and prognosis, as well as novel targeted therapies.
SGLT2 inhibitors and novel biomarkers represent promising strategies for the early diagnosis and management of cardiorenal syndrome.
Answers are grounded in this paper and cite their sources.
Does not support practice changes in cardiorenal syndrome; leaves open optimal SGLT2i use and biomarker integration pending RCTs.
Cardiorenal syndrome consists in the coexistence of acute or chronic dysfunction of heart and kidneys resulting in a cascade of feedback mechanisms and causing damage to both organs associated with high morbidity and mortality. In the last few years, different biomarkers have been investigated with the aim to achieve an early and accurate diagnosis of cardiorenal syndrome, to provide a prognostic role and to guide the development of targeted pharmacological and non-pharmacological therapies. In such a context, sodium-glucose cotransporter 2 (SGLT2) inhibitors, recommended as the first-line choice in the management of heart failure, might represent a promising strategy in the management of cardiorenal syndrome due to their efficacy in reducing both cardiac and renal outcomes. In this review, we will discuss the current knowledge on the pathophysiology of cardiorenal syndrome in adults, as well as the utility of biomarkers in cardiac and kidney dysfunction and potential insights into novel therapeutics.
No takes yet. Share an insight, caveat, or question.
Gallo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: